Sucroferric oxyhydroxide use in patients on haemodialysis – real-world experience from an Asian cohort

Abstract

Background Sucroferric oxyhydroxide has been used in the treatment of hyperphosphataemia in adult patients with chronic kidney disease receiving haemodialysis or peritoneal dialysis since 2013. However, there is a paucity of data on sucroferric oxyhydroxide use in Asian populations. Objective We aim to provide real-world experience of sucroferric oxyhydroxide use in our local cohort on maintenance haemodialysis. Methods A retrospective clinical audit was performed to review laboratory parameters of haemodialysis patients who received sucroferric oxyhydroxide over a 14-month period from December 2020 to January 2022. Sucroferric oxyhydroxide reduced serum phosphate levels effectively, with a more than 3-fold increase in the proportion of patients who were able to achieve phosphate levels of ≤5.5 mg/dL. Ferritin levels and transferrin saturation were increased, but there were no significant differences in haemoglobin levels and erythropoietin used in the long term. We showed that sucroferric oxyhydroxide was highly effective in reducing serum phosphate to recommended levels in patients receiving haemodialysis. Further prospective studies in Asian populations are warranted to confirm our findings.